Brief: Matinas Biopharma Announces Unanimous Dsmb Approval To Progress Into Second Cohort Of Patients In The Enact Study Of Mat2203 For The Treatment Of Cryptococcal Meningitis

Matinas BioPharma Holdings

19/10/2020 11:37

Oct 19 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES UNANIMOUS DSMB APPROVAL TO
PROGRESS
INTO SECOND COHORT OF PATIENTS IN THE ENACT STUDY OF MAT2203
(ORAL AMPHOTERICIN B) FOR THE TREATMENT OF CRYPTOCOCCAL
MENINGITIS
    * MATINAS BIOPHARMA HOLDINGS - ENROLLMENT IN SECOND COHORT
OF
PATIENTS EXPECTED TO COMMENCE IMMINENTLY WITH NEXTDSMB
EVALUATION ANTICIPATED MID-2021

Source text for Eikon:  ID:nGNX8Y6npR 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))